- Home
- ALKT vs ARWR Comparison
ALKT vs ARWR Comparison
Compare ALKT & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALKT
- ARWR
- Stock Information
- Founded
- ALKT 2007
- ARWR 2003
- Country
- ALKT United States
- ARWR United States
- Employees
- ALKT N/A
- ARWR N/A
- Industry
- ALKT EDP Services
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- ALKT Technology
- ARWR Health Care
- Exchange
- ALKT Nasdaq
- ARWR Nasdaq
- Market Cap
- ALKT 2.6B
- ARWR 2.5B
- IPO Year
- ALKT 2021
- ARWR 1993
- Fundamental
- Price
- ALKT $26.60
- ARWR $30.72
- Analyst Decision
- ALKT Buy
- ARWR Strong Buy
- Analyst Count
- ALKT 9
- ARWR 8
- Target Price
- ALKT $39.89
- ARWR $47.75
- AVG Volume (30 Days)
- ALKT 1.3M
- ARWR 2.8M
- Earning Date
- ALKT 10-29-2025
- ARWR 08-07-2025
- Dividend Yield
- ALKT N/A
- ARWR N/A
- EPS Growth
- ALKT N/A
- ARWR N/A
- EPS
- ALKT N/A
- ARWR N/A
- Revenue
- ALKT $385,456,000.00
- ARWR $572,976,000.00
- Revenue This Year
- ALKT $36.04
- ARWR $21,619.52
- Revenue Next Year
- ALKT $24.93
- ARWR N/A
- P/E Ratio
- ALKT N/A
- ARWR N/A
- Revenue Growth
- ALKT 29.63
- ARWR 2816.20
- 52 Week Low
- ALKT $19.94
- ARWR $9.57
- 52 Week High
- ALKT $42.29
- ARWR $31.13
- Technical
- Relative Strength Index (RSI)
- ALKT 62.50
- ARWR 74.54
- Support Level
- ALKT $24.88
- ARWR $28.12
- Resistance Level
- ALKT $26.78
- ARWR $31.13
- Average True Range (ATR)
- ALKT 0.75
- ARWR 1.60
- MACD
- ALKT 0.17
- ARWR 0.13
- Stochastic Oscillator
- ALKT 90.91
- ARWR 97.37
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company's solution, the Alkami Digital Banking Platform, allows FIs to onboard and engage new users, accelerate revenues and meaningfully improve operational efficiency, all with the support of a proprietary, true cloud-based, multi-tenant architecture.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.